Evidence map›Paper›PMID 39095538›Full record

ArticleScientific reports2024

Immunoinformatics design and synthesis of a multi-epitope vaccine against Helicobacter pylori based on lipid nanoparticles.

Ali Jebali, Azam Esmaeilzadeh, Mohamad Kazem Esmaeilzadeh, Sadeq Shabani

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Beyond Antibiotics: Alternative Strategies TargetingExpert reviews in molecular medicine · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. UnravelingVaccines · 2025
    Review
  7. Article
  8. Vaccines · 2025
    Review
  9. Review
  10. Construction and evaluation of aFrontiers in immunology · 2025
    Article
  11. Biotechnologia · 2025
    Article
  12. Article
  13. Adjuvants forVirulence · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ali JebaliDepartment of Medical Nanotechnology, Faculty of Advanced Sciences and Technology, Tehran Medical Science, Islamic Azad University, Tehran, Iran.
Azam EsmaeilzadehDepartment of Nanobiomimetics, Faculty of Advanced Sciences and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. esmaeilzadeh2016@gmail.com.
Mohamad Kazem EsmaeilzadehEeducational and Hospital Pharmacies Complex, Isfahan University of Medical Sciences, Isfahan, Iran.
Sadeq ShabaniDepartment of Biological Sciences, Bio-molecular Science Institute, Florida International University, Miami, FL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Helicobacter pylori (H. pylori) is responsible for various chronic or acute diseases, such as stomach ulcers, dyspepsia, peptic ulcers, gastroesophageal reflux, gastritis, lymphoma, and stomach cancers. Although specific drugs are available to treat the bacterium's harmful effects, there is an urgent need to develop a preventive or therapeutic vaccine. Therefore, the current study aims to create a multi-epitope vaccine against H. pylori using lipid nanoparticles. Five epitopes from five target proteins of H. pylori, namely, Urease, CagA, HopE, SabA, and BabA, were used. Immunogenicity, MHC (Major Histocompatibility Complex) bonding, allergenicity, toxicity, physicochemical analysis, and global population coverage of the entire epitopes and final construct were carefully examined. The study involved using various bioinformatic web tools to accomplish the following tasks: modeling the three-dimensional structure of a set of epitopes and the final construct and docking them with Toll-Like Receptor 4 (TLR4). In the experimental phase, the final multi-epitope construct was synthesized using the solid phase method, and it was then enclosed in lipid nanoparticles. After synthesizing the construct, its loading, average size distribution, and nanoliposome shape were checked using Nanodrop at 280 nm, dynamic light scattering (DLS), and atomic force microscope (AFM). The designed vaccine has been confirmed to be non-toxic and anti-allergic. It can bind with different MHC alleles at a rate of 99.05%. The construct loading was determined to be about 91%, with an average size of 54 nm. Spherical shapes were also observed in the AFM images. Further laboratory tests are necessary to confirm the safety and immunogenicity of the multi-epitope vaccine.

Indexed as

Bacterial VaccinesComputational BiologyHelicobacter pyloriNanoparticlesAntigens, BacterialBacterial ProteinsEpitopesHelicobacter InfectionsHumansImmunoinformaticsLiposomesMolecular Docking SimulationToll-Like Receptor 4UreaseAntigens, BacterialBacterial ProteinsBacterial VaccinescagA protein, Helicobacter pyloriEpitopesLipid NanoparticlesLiposomesToll-Like Receptor 4UreaseHelicobacter pyloriImmunoinformaticsMulti-epitopeVaccine

Identifiers

PMID39095538
PMCPMC11297249

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.